EU Approves Gilead’s Remdesivir For COVID-19 In Record Time

Despite The Controversy, Blockbuster Status Is Predicted

The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about €2,000 per treatment.

Vials_Remdesivir
There are concerns over the supply of remdesivir for COVID-19 • Source: Shutterstock

The European Commission's decision to issue a conditional marketing authorization for Gilead Sciences Inc.'s COVID-19 therapy, Viklury (remdesivir), comes just eight days after the European Medicines Agency's drug evaluation committee, the CHMP, delivered a positive opinion on the product's approval. In normal circumstances the commission has 67 days in which to grant an MA after a CHMP recommendation. (Also see "Remdesivir’s EU Approval For COVID-19 Due Within Days" - Pink Sheet, 25 June, 2020.) 

The decision also comes just two days after Gilead announced that the US government had bought up nearly all of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography